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The in vitro susceptibilities of 66 molecularly identified strains of theMucorales to eight antifungals (amphotericin B, terbin-
afine, itraconazole, posaconazole, voriconazole, caspofungin,micafungin, and 5-fluorocytosine)were tested.Molecular phylogenywas
reconstructed based on the nuclear ribosomal large subunit to reveal taxon-specific susceptibility profiles. The impressive phylogenetic
diversity of theMucoraleswas reflected in susceptibilities differing at family, genus, and species levels. AmphotericinBwas themost
active drug, though somewhat less againstRhizopus andCunninghamella species. Posaconazolewas the secondmost effective antifun-
gal agent but showed reduced activity inMucor andCunninghamella strains, while voriconazole lacked in vitro activity formost
strains. Genera attributed to theMucoraceae exhibited awide range ofMICs for posaconazole, itraconazole, and terbinafine and in-
cluded resistant strains.Cunninghamella also comprised strains resistant to all azoles tested butwas fully susceptible to terbinafine. In
contrast, the Lichtheimiaceae completely lacked strainswith reduced susceptibility for these antifungals. Syncephalastrum species ex-
hibited susceptibility profiles similar to those of the Lichtheimiaceae.Mucor speciesweremore resistant to azoles thanRhizopus spe-
cies. Species-specific responses were obtained for terbinafine where onlyRhizopus arrhizus andMucor circinelloideswere resistant.
Complete or vast resistancewas observed for 5-fluorocytosine, caspofungin, andmicafungin. Intraspecific variability of in vitro sus-
ceptibilitywas found in all genera tested butwas especially high inMucor andRhizopus for azoles and terbinafine. Accuratemolecular
identification of etiologic agents is compulsory to predict therapy outcome. For species of critical genera such asMucor andRhizopus,
exhibiting high intraspecific variation, susceptibility testing before the onset of therapy is recommended.
The fungal order Mucorales, belonging to a section of lowerfungi that until recently was referred to as zygomycetes, con-
stitutes a phylogenetically ancient group of organisms. In the fun-
gal tree of life the group encompasses a number of widely spaced,
ancestral lineages. Over time, mutations are hypothesized to have
accumulated, which is reflected, e.g., in an immense degree of
sequence diversity of evolutionary markers such as the ribosomal
operon. By assessment of identical genes, mucoralean species are
separated from each other at branches much longer than those of
species of more recent fungi, such as Aspergillus or the dermato-
phytes. As a result, ancestry is difficult to reconstruct, leading to phy-
logenetic trees with poorly resolved backbones. For similar reasons,
the phylumZygomycota has been abandoned: phylogenetic distances
are so large that no taxonomic hierarchy can be constructed and no
umbrella group defined that would unite all fungi attributed to the
Zygomycota in the classical sense (23).
The opportunistic members of theMucorales are classified in the
families Cunninghamellaceae, Lichtheimiaceae, Mucoraceae, Saksen-
aceae, and Syncephalastraceae, with the great majority of human in-
fections being caused by members of Mucoraceae and Lichtheimi-
aceae. In molecular phylogenetic analyses (31, 43), the genus
Rhizomucorwas positioned outside theMucoraceae, and in the pres-
ent article the Index Fungorum (http://www.indexfungorum.org) is
followed, classifying the genus in the Lichtheimiaceae.
Infections generally occur in severely debilitated patients and
are acute, destructive, and with a rapid course and fatal outcome
(14, 37). In general, different types of underlying conditions pre-
dispose for different types of infection. Major skin abrasion and
burn wounds may lead to erosive subcutaneous infection. Rhino-
cerebral and pulmonary infection are linked to ketoacidotic dia-
betes and severe neutropenia, respectively, while immunosup-
pression and prolonged deferoxamine therapy predispose for
disseminated infection (11). Chronic disorders observed in indi-
viduals without severe immune or metabolic dysfunction are ex-
ceptional cases (25). Also, renal mucormycosis tends to occur in
immunocompetent individuals (21, 27).
Given the enormous phylogenetic diversity of the Mucorales
(31, 43), it is remarkable that frequent case reports appear refer-
ring to the etiologic agent without proper species identification
(e.g., references 19 and 26). Practical reasons for this are the diffi-
culties of cultivating these fungi from biopsy samples (22, 34) and
of differentiating zygomycete species by classical mycological
techniques in clinical microbiology laboratories. Previous com-
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prehensive studies on susceptibility profiles against antifungal
drugs in theMucorales revealed considerable variation among and
within genera and species, as defined either by applying classical
parameters (5, 16, 35, 39, 40) or more recently by usingmolecular
taxonomic methods (1, 12). A recent review of in vitro activity of
antifungals against zygomycetes was provided by Alastruey-
Izquierdo et al. (2).
Application of molecular methods for species identification in
Mucorales frequently leads to the unexpected detection of novel
sibling species (3, 6, 9). For this reason, and because of the diffi-
culty of morphological species identification, studies on the taxon
specificity of susceptibility profiles in this group of fungi need to
be preceded bymolecular identification of the strains under study
(1). Otherwise, in clinical practice, when the only intention is to
determine the most appropriate antifungal as quickly as possible,
susceptibility tests could also be performed directly. We chose the
internal transcribed spacer (ITS) region for taxonomy at the spe-
cies level because it earlier has been shown to be the speciesmarker
of choice inMucorales (36).
Classification ofMucorales above the species level is in a state of
flux, sincemolecular phylogenetic analyses found polyphyly of the
majority of morphology-based families and genera (31, 41). The
D1/D2 region of the nuclear ribosomal large subunit (LSU) was
chosen to reconstruct phylogeny because it could be sequenced
directly, while all protein-encoding genes tested revealed paralogs
in numerous species (3). Furthermore, the LSU is alignable over
the entire order. A robust molecular phylogenetic hypothesis is
necessary to address the main question of this study: do phyloge-
netic taxa (species, genera, and families) of theMucorales possess
more or less characteristic susceptibility profiles?
MATERIALS AND METHODS
Strains. All isolates used in this study were taken from the reference col-
lection of the CBS-KNAWFungal Biodiversity Centre (CBS, Utrecht, The
Netherlands), from the Institut Pasteur (CNRMA/IP, Paris, France), or
from the American Type Culture Collection (ATCC, Manassas, VA).
Strains selected for phylogenetic reconstruction represented all relevant
taxa of theMucorales including the clinically relevant species.
Extraction of genomic DNA, amplification, cloning, and sequenc-
ing. Genomic DNA was extracted from 2-day-old malt extract agar
(MEA) cultures according to the procedure reported by Möller et al. (28)
with severalmodifications described in detail byAlastruey-Izquierdo et al.
(3). DNA segments comprising the complete ITS region and the D1/D2
region of the LSUwere amplified using the primer pair V9G (18) and LR3
(41). The PCRmixture (25l) contained 0.4Meach primer, 0.185 mM
each deoxynucleoside triphosphate (GC Biotech, Alphen a/d Rijn, The
Netherlands), 10NH4BioTaq reaction buffer (GCBiotech), a final con-
centration of 1.5 mM MgCl2, 0.8 U BioTaq DNA polymerase (GC Bio-
tech), and about 20 ng DNA. The cycling conditions included one initial
cycle at 94°C for 5 min, followed by 35 cycles of 1 min at 94°C, 1 min at
53°C, and 2 min at 72°C, with one final cycle of 7 min at 72°C. PCRs were
performed on a thermal cycler 2720 (Applied Biosystems, Nieuwerkerk
a/d IJssel, The Netherlands). Reaction products were analyzed in 1% aga-
rose gels. Both strands of the PCR products were directly cycle sequenced
using the BigDye sequencing kit (Applied Biosystems), and the primer set
ITS1 and ITS4 (44) for the complete ITS region and NL1 and LR3 for the
D1/D2 region of the LSU (30) were used. Cycle-sequencing products were
analyzed on an ABI 3730XL automatic sequencer (Applied Biosystems).
In a few cases, direct sequencing failed and the PCR products were cloned
in the competent Escherichia coli cell line JM109 by using the pGEM-T
Easy vector (Promega, Leiden, The Netherlands) as instructed by the
manufacturer. Colony PCRs were performed using the primer pair M13f
(5=-GTAAAACGACGGCCAGT-3=) and M13r (5=-GGAAACAGCTATG
ACCATG-3=). Products of colony PCRs were sequenced as described
above.
Species identification and phylogenetic analysis. Consensus se-
quences were constructed by means of the SeqMan program v.7.2.2.
(DNASTAR, Lasergene). TheD1/D2 region of the LSUwas used to recon-
struct the phylogeny of the Mucorales, while the ITS region served as a
marker for molecular species recognition. For both markers, sequences
were aligned using the server version of theMAFFT program (http://www
.ebi.ac.uk/Tools/mafft) and manually corrected in the program Se-Al
v2.0a11 (http://tree.bio.ed.ac.uk/software/seal/) (33). Sequences of the
ITS spacers were not alignable over the entire order. Therefore, ITS align-
ments for each studied genus were prepared including sequences of all
relevant ex-type strains to ensure an accurate identification. They were
rooted by the nearest neighbors according to the work of O’Donnell et al.
(31). Phylogenetic relationships were estimated using the maximum like-
lihoodmethod with the server version of RAxML-VI-HPC v.7.0.0 (38), as
implemented on the Cipres portal. The robustness of the trees was esti-
mated by a bootstrap analysis with 1,000 replicates.
In vitro susceptibility testing. A set of 66 strains was tested (Table 1),
including species of Cunninghamella (n  8), Lichtheimia (syn. Absidia
pro parte, Mycocladus) (n  13), Mucor (n  12), Rhizomucor (n  8),
Rhizopus (n 19), and Syncephalastrum (n 6). In vitro susceptibilities
were determined by a brothmicrodilution technique following the guide-
lines of the Clinical and Laboratory Standards Institute (CLSI) M38A
document (29) with few modifications. RPMI 1640 medium with
L-glutamine but without sodium bicarbonate (Sigma-Aldrich, Saint
Quentin Fallavier, France) buffered to pH 7.0 with 0.165MMOPS (mor-
pholinepropanesulfonic acid) (Sigma-Aldrich) was used as the test me-
dium. Isolates were grown on Sabouraud dextrose agar for 7 days at 30°C,
and stock spore suspensions were prepared by washing the surface of the
slants with sterile saline containing 0.05% Tween 80. Spore suspensions
were countedwith a hemacytometer and then diluted into RPMImedium
to a concentration of 2  104 spores/ml (2 final concentration). Pure
powders of known potency of amphotericin B (AMB; Sigma-Aldrich,
Saint Quentin Fallavier, France), voriconazole (VCZ; Pfizer Central Re-
search, Sandwich, United Kingdom), itraconazole (ITZ; Janssen-Cilag,
Issy-les-Moulineaux, France), posaconazole (PCZ; Schering-Plough, Ke-
nilworth, NJ), 5-fluorocytosine (5-FC; Sigma-Aldrich), terbinafine (TBF;
Novartis Pharma, Basel, Switzerland), caspofungin (CAS; Merck, Rah-
way, NJ), and micafungin (MCF; Astellas Pharma, Inc., Ibaraki, Japan)
were used.
Briefly, microplates containing the antifungal drugs were prepared by
batch and stored frozen at20°C for less than 1 month. MIC endpoints
were determined by an automated microplate reader spectrophotometer
(Multiscan RC-351; Labsystems Oy, Helsinki, Finland) after 24 h of incu-
bation (an optical density [OD] of 0.15 was required for the drug-free
control wells) at 35°C (28°C forMucor and Rhizomucor). MIC endpoints
were defined as 50% reduction in growth compared to the drug-free
wells, except for AMB, for which a 90% reduction endpoint was used. For
echinocandins, minimum effective concentrations (MECs) were deter-
mined by reading the microplates with the aid of an inverted microscope.
Two reference strains, Candida krusei ATCC 6258 and Candida parapsi-
losis ATCC 22019, were included in each set of determinations to ensure
quality control.
Statistics. For calculation purposes, high off-scale MICs/MECs were
raised to the next higher concentration, while low off-scaleMICs were left
unchanged. Associations between the phylogenetic order andMICs of the
various antifungal agents were tested with the two-tailed Mann-Whitney
test using GraphPad InStat version 3.00 (GraphPad Instat Software, Inc.,
San Diego, CA).
Nucleotide sequence accession numbers. Sixty LSU sequences
(GenBank accession numbers HM849659 to HM849674, HM849676 to
HM849707, HM849709, HM849710, and HM849715 to HM849724)
and 38 ITS sequences (GenBank accession numbers HM999950 to
HM999986 and HQ186304) were newly generated for this study.
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TABLE 1 Strains analyzed with present molecular identification and in vitro susceptibility dataa
Name Strain Source Country
MIC/MEC (g/ml) for:
5-FC MCF CAS TBF VCZ ITZ PCZ AMB
Mucoraceae
Mucor
M. circinelloides (syn.
Rhizomucor regularior)
CBS 384.95 T Human, face China 64 4 4 16 8 4 1 0.25
M. circinelloides CBS 416.77 Fermenting rice Unknown 64 4 4 4 8 2 1 0.5
M. circinelloides CNRMA 03.154 Human, skin France 64 4 4 32 8 1 0.5 0.25
M. circinelloides CNRMA 03.371 Human, muscle France 64 4 4 2 8 2 1 0.5
M. circinelloides f.
circinelloides
CBS 195.68 NT Air Netherlands 64 4 4 32 8 1 1 0.25
M. circinelloides IP 1873.89 Human, feces France 64 4 4 32 8 2 1 0.25
M. circinelloides CNRMA 04.805 Human, muscle France 64 4 4 2 8 2 2 0.5
M. ramosissimus CBS 135.65 NT Human, nasal lesion Uruguay 64 4 4 2 8 1 1 0.25
M. racemosus f.
racemosus
CBS 260.68 T Unknown Switzerland 64 4 4 0.125 2 0.25 0.125 0.5
M. hiemalis f. hiemalis CBS 201.65 NT Unknown USA 64 4 4 0.25 1 0.5 0.5 0.5
M. irregularis (syn.
Rhizomucor variabilis)
CBS 103.93 T Human, hand China 64 4 4 0.5 8 1 1 0.5
M. indicus CNRMA 03.894 Human, muscle France 64 4 4 0.5 8 1 1 0.5
Rhizopus
R. arrhizus IP 4.77 Human, brain France 64 4 4 32 8 0.5 0.5 1
R. arrhizus CNRMA 03.413 Unknown France 64 4 4 32 4 0.5 0.25 0.5
R. arrhizus CNRMA 03.410 Human, sputum France 64 4 4 32 8 1 0.5 1
R. arrhizus CNRMA 03.412 Human, sputum France 64 4 4 1 4 0.5 0.125 1
R. arrhizus CBS 112.07 T Unknown Netherlands 64 4 4 32 8 0.5 0.5 1
R. arrhizus CNRMA 03.411 Human, sputum France 64 4 4 4 8 0.5 0.25 1
R. arrhizus CNRMA 04.48 Human, skin France 64 4 4 32 8 0.5 0.25 2
R. arrhizus CNRMA 04.160 Human, sputum France 64 4 4 16 8 0.5 0.25 1
R. arrhizus CNRMA 03.253 Human, lung France 64 4 4 4 4 0.25 0.03 1
R. arrhizus CNRMA 03.395 Human, skin France 64 4 4 32 4 0.5 0.25 1
R. arrhizus CNRMA 03.375 Human, sinus France 64 4 4 32 8 1 0.5 2
R. arrhizus CNRMA 03.909 Human, sinus France 64 4 4 8 4 0.5 0.25 0.5
R. arrhizus IP 1443.83 Unknown Unknown 64 4 4 2 4 0.125 0.5 0.5
R. arrhizus CNRMA 03.918 Human, lung France 64 4 4 32 8 1 0.5 1
R. microsporus var.
azygosporus
CBS 357.93 T Tempeh Indonesia 64 4 4 0.125 4 0.5 0.5 1
R. microsporus var.
rhizopodiformis
CNRMA 04.1469 Human France 64 4 4 0.125 8 4 2 2
R. microsporus var.
chinensis
CBS 631.82 T Bread China 64 4 4 0.25 4 1 0.5 1
R. microsporus var.
rhizopodiformis
IP 1123.75 Unknown Unknown 64 4 4 0.06 4 0.5 0.5 1
R. microsporus var.
rhizopodiformis
IP 676.72 Human, skin France 64 4 4 0.125 4 0.5 0.25 1
Syncephalastraceae
Syncephalastrum
S. “racemosum”
(species II)
CBS 199.81 Soil Kuwait 64 4 4 0.25 8 0.5 0.25 0.06
S. “racemosum”
(species II)
CBS 421.63 Soil Zaire 64 4 4 0.25 8 0.5 0.5 0.03
S. “racemosum”
(species I)
CBS 302.65 Soil Brazil 64 4 4 0.25 8 0.5 1 0.25
Continued on following page
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RESULTS
The LSU tree (Fig. 1) comprises members of the clinically signif-
icant genera Apophysomyces, Cokeromyces, Cunninghamella, Lich-
theimia, Mucor, Rhizomucor, Rhizopus, Saksenaea, and Synceph-
alastrum, all belonging to the orderMucorales. Sequences could be
aligned with relative confidence but showed considerable diver-
sity. In contrast, morphological identification of species appeared
to be nonpredictive, with extreme differences occurring between
neighboring molecular taxa. Ribosomal DNA (rDNA) distances
between species belonging to a single genuswere considerable. ITS
diversity was up to 20% in Lichtheimia and 35% in Mucor, while
Rhizopus arrhizus and Rhizopus microsporus deviated 29.8% (data
not shown). ITS sequences showed very limited similarity over the
entire data set and could not be aligned. Separate trees were there-
fore constructed for molecular identification (Fig. 2).
With a single exception, all strains included in susceptibility
TABLE 1 (Continued)
Name Strain Source Country
MIC/MEC (g/ml) for:
5-FC MCF CAS TBF VCZ ITZ PCZ AMB
S. “racemosum”
(species I)
CBS 441.59 Dung of coyote USA 64 4 4 0.25 8 0.5 0.25 0.06
S. “racemosum”
(species I)
CNRMA 03.414 Human, skin France 64 4 4 0.06 1 0.03 0.06 0.25
S. “racemosum”
(species I)
CBS 370.49 Air Indonesia 64 4 4 0.125 8 0.25 0.5 0.06
Lichtheimiaceae
Rhizomucor
R. pusillus CBS 354.68 NT Corn meal Netherlands 64 4 4 0.125 2 0.25 0.25 0.5
R. pusillus CNRMA 04.210 Human, bone France 64 4 4 0.125 8 0.25 0.25 0.5
R. pusillus CNRMA 04.503 Human, sputum France 64 4 4 0.125 2 0.25 0.5 0.5
R. pusillus IP 1956.90 Human, bronchia France 64 4 4 0.125 2 0.25 0.25 0.5
R. pusillus ATCC 36606 Cat, brain France 64 4 4 0.06 4 0.25 0.125 0.5
R. pusillus CNRMA 03.1205 Human, lung France 64 4 4 0.125 2 0.25 0.25 0.5
R. pusillus IP 1127.75 Unknown Unknown 64 4 4 0.06 4 0.25 0.125 0.5
R. miehei CBS 182.67 T Retting plant USA 64 4 4 0.25 4 0.06 0.125 0.5
Lichtheimia CNRMA 03.611 Human, bronchia France 64 4 4 0.06 8 0.125 0.25 0.5
L. corymbifera IP 1129.75 Air Morocco 64 4 4 0.125 8 0.25 0.25 0.25
L. corymbifera CNRMA 03.697 Human, bone France 64 4 4 0.125 8 0.25 0.25 0.25
L. corymbifera IP 1279.81 Unknown Unknown 64 4 4 0.125 8 0.25 0.06 0.25
L. corymbifera CNRMA 04.732 Human, lung France 64 4 4 0.25 8 0.25 0.25 0.5
L. corymbifera IP 1280.81 Unknown Unknown 64 4 4 0.125 8 0.25 0.25 0.25
L. ramosa CBS 100.55 Unknown Unknown 64 4 4 0.12 8 0.5 0.06 0.125
L. ramosa CBS 100.49 Dung of cow Indonesia 64 4 4 0.25 2 0.03 0.06 0.06
L. ramosa CBS 124198 Culture contaminant Netherlands 64 4 4 0.25 2 0.12 0.06 0.25
L. ramosa CBS 582.65 NT Cacao seeds Ghana 64 4 4 0.5 8 0.5 0.25 0.125
L. ramosa CBS 223.78 Soil Unknown 64 4 4 0.25 8 0.25 0.25 0.125
L. ornata CBS 958.68 Unknown Unknown 64 4 4 0.25 2 0.06 0.06 0.25
L. ornata CBS 291.66 T Dung of bird India 64 4 4 0.25 8 0.12 0.06 0.25
Cunninghamellaceae
Cunninghamella
C. bertholletiae CBS 186.84 Human, lung USA 64 4 4 0.06 8 16 1 2
C. bertholletiae CBS 693.68 Soil Yugoslavia 64 4 4 0.25 8 64 1 1
C. bertholletiae CBS 372.95 Soil China 64 4 4 0.06 8 16 0.5 1
C. bertholletiae CBS 190.84 Human, heart USA 64 4 4 0.06 8 16 0.5 2
C. bertholletiae CBS 191.84 Human, tibia USA 32 1 4 0.06 8 64 0.5 2
C. echinulata var.
antarctica
CBS 545.75 Soil Chile 64 4 4 0.125 8 1 0.5 2
C. echinulata CBS 766.68 Unknown Unknown 64 4 4 0.06 8 64 1 1
C. echinulata CBS 156.28 Unknown Unknown 64 0.5 4 0.25 8 16 1 2
a Susceptibility data are in g/ml for 5-fluorocytosine (5-FC), micafungin (MCF), caspofungin (CAS), terbinafine (TBF), voriconazole (VCZ), itraconazole (ITZ), posaconazole
(PCZ), and amphotericin B (AMB). Genera are placed in line with the phylogenetic tree of Fig. 1 except for Rhizomucor. Within the genera, strains are arranged according to their
position in the trees of Fig. 2. Species boundaries are marked by vertical space. NT, neotype; T, ex-type.
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testing could be identified reliably to the species level by using the
ITS region, because of their position in shared clades with ex-type
strains (Fig. 2). The correct identification of Syncephalastrum rac-
emosum turned out to be problematic because this species has not
been typified yet, and strains morphologically identified as Syn-
cephalastrum racemosum formed two clearly separate clades in the
ITS tree (Fig. 2f): some S. racemosum strains were part of a well-
supported clade with Syncephalastrum monosporum, while others
(including the clinical strain CNRMA03.414), represented by two
types of ITS sequences (note different clone numbers of the same
FIG 1 RAxML phylogram based on the D1/D2 region of the LSU. Branches with bootstrap values of 85 or higher are printed in bold. Important branch support
values lower than 85 are indicated by numbers near the branches. Ex-type strains are indicated by T (type strain), NT (neotype strain), IT (isotype strain), and
HT (holotype strain) following the strain numbers. Asterisks indicate strains included in the susceptibility study. Bars (a to f) mark the genera represented by an
ITS dendrogram in Fig. 2.
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FIG 2 RAxML phylograms based on the complete ITS region. Branches with bootstrap values of 85 or higher are printed in bold. In cases of less space or
important values lower than 85, branch support values are indicated by numbers near the branches. Ex-type strains are printed in bold and indicated by T (type
strain), NT (neotype strain), IT (isotype strain), and HT (holotype strain) following the strain numbers. Asterisks indicate strains included in the susceptibility
study. Clones are specified by a “c” followed by the clone number.
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strains), formed a second group. Syncephalastrum racemosum has
been described by Schroeter (original reference cited in reference
13) as “inter Aspergillus oryzae in Oryza et pane,” i.e., on moldy
rice and bread, inWroclaw, Poland, andno typematerial is known
to be preserved. None of the isolates studied morphologically
completely matched the description given by Schroeter, and
more-detailed taxonomic studies are needed to select a neotype
for this species. Therefore, we designate the putative species in
the following as Syncephalastrum “racemosum” species I and S.
“racemosum” species II.
Judging from LSU and ITS phylograms (Fig. 1, 2) Rhizomucor
regularior and Rhizomucor variabilis were found to be related to
Mucor but belonged to the species complexes of M. circinelloides
and M. hiemalis, respectively; R. variabilis has recently been re-
named as M. irregularis, and R. regularior has been synonymized
with M. circinelloides (9). The genus Rhizomucor is restricted to
thermophilic species forming spherical spores, such as R. pusillus
and R. miehei. Mucor ramosissimus belongs to M. circinelloides.
The varieties azygosporus, chinensis, rhizopodiformis, and tuberosus
of Rhizopus microsporus possessed identical ITS sequences and
could not be discriminated molecularly (Fig. 2b). Therefore, the
morphology-based assignment to the varieties was retained. In
Rhizopus arrhizus (syn. R. oryzae), small molecular differences be-
tween varieties were observed, but because of the limited number
of reference strains available representing each of the varieties,
identifications were done at the species level only.
A total of eight antifungal compounds were tested on six mu-
coralean genera: Mucor and Rhizopus (Mucoraceae), Lichtheimia
and Rhizomucor (Lichtheimiaceae), Syncephalastrum (Syncephala-
straceae), and Cunninghamella (Cunninghamellaceae). The Cun-
ninghamellaceae and the Syncephalastraceae are unigeneric, and
conclusions drawn on the genus are also valid for the family. The
positions of the genera in Tables 1 and 2 refer to their positions in
the LSU phylogram of Fig. 1, except for Rhizomucor. Rhizomucor
as a member of the Lichtheimiaceae is placed with Lichtheimia
because its position closer to Circinella in the LSU phylogram is
not supported. Within the genera, strains are arranged according
to their position in the phylogenetic trees of Fig. 2. Because clinical
breakpoints for filamentous fungi have not been assigned to the
majority of antifungals, we refer to those given by Almyroudis et
al. (5) and deHoog et al. (17), viz.AMB 1; CAS 2; 5-FC 16;
ITC 0.5; PCZ 0.5; and VRC 2.
For 5-FC, MCF, and CAS, little variation in susceptibility was
noted: for 5-FC and CAS, all strains showed high MIC/MEC val-
ues of 32 to 64 and 4 g/ml, respectively. Except for two
strains of Cunninghamella, high MEC values (4 g/ml) were
also obtained for MCF. All strains included in this study were
resistant or less susceptible to VCZ.
For the remaining compounds, considerable variation was
found at the family and generic levels inferred from the LSU phy-
logram. Overall, AMB in vitro was the most effective antifungal
agent againstMucorales, but its efficacy proved to be ambiguous in
Rhizopus and Cunninghamella, where relatively high MICs were
obtained. Three out of 19Rhizopus strains and 5 out of 8Cunning-
hamella strains tested had MICs of 2 g/ml, exceeding the as-
sumed breakpoint for this drug. MICs of these two genera were
significantly elevated when compared to the other Mucorales, for
which the amphotericin B MICs ranged between 0.03 and 0.5
g/ml (Mann-Whitney, P  0.0001 for both genera). Together
with those for posaconazole, amphotericin B MICs showed the
TABLE 2MIC ranges and geometric means (GMs) for genera and species inferred from the phylogramsa
Name (no. of strains)
MIC range (GM) (g/ml) for:
5-FC MCF CAS TBF VCZ ITZ PCZ AMB
Mucor (12) 64 (64) 4 (4) 4 (4) 0.125–32 (2.69) 1–8 (6.0) 0.25–4 (1.19) 0.125–2 (0.79) 0.25–0.5 (0.37)
Mucor circinelloides sensu
lato (8)
64 (64) 4 (4) 4 (4) 2–32 (8) 8 (8) 1–4 (1.68) 0.5–2 (1) 0.25–0.5 (0.32)
Mucor racemosus (1) 64 4 4 0.125 2 0.25 0.125 0.5
Mucor hiemalis (1) 64 4 4 0.25 1 0.5 0.5 0.5
Mucor irregularis (1) 64 4 4 0.5 8 1 1 0.5
Mucor indicus (1) 64 4 4 0.5 8 1 1 0.5
Rhizopus (19) 64 (64) 4 (4) 4 (4) 0.06–32 (3.84) 4–8 (5.5) 0.125–4 (0.58) 0.03–2 (0.33) 0.5–2 (1)
Rhizopus arrhizus (14) 64 (64) 4 (4) 4 (4) 1–32 (21.11) 4–8 (5.9) 0.125–1 (0.5) 0.03–0.5 (0.28) 0.5–2 (0.95)
Rhizopus microsporus (5) 64 (64) 4 (4) 4 (4) 0.06–0.25 (0.12) 4–8 (4.6) 0.5–4 (0.87) 0.25–2 (0.57) 1–2 (1.15)
Syncephalastrum (6) 64 (64) 4 (4) 4 (4) 0.06–0.25 (0.18) 1–8 (5.6) 0.03–0.5 (0.28) 0.06–1 (0.31) 0.03–0.25 (0.09)
Syncephalastrum “racemosum”
species II (2)
64 4 4 0.25 8 0.5 0.25–5 0.03–0.06
Syncephalastrum “racemosum”
species I (4)
64 (64) 4 (4) 4 (4) 0.06–0.25 (0.15) 1–8 (4.7) 0.03–0.5 (0.21) 0.06–1 (0.29) 0.06–0.25 (0.12)
Rhizomucor (8) 64 (64) 4 (4) 4 (4) 0.06–0.25 (0.11) 2–8 (3.1) 0.06–0.25 (0.21) 0.125–0.5 (0.21) 0.5 (0.5)
Rhizomucor pusillus (7) 64 (64) 4 (4) 4 (4) 0.06–0.125 (0.1) 2–8 (3.0) 0.25 (0.25) 0.125–0.5 (0.23) 0.5 (0.5)
Rhizomucor miehei (1) 64 4 4 0.25 4 0.06 0.125 0.5
Lichtheimia (13) 64 (64) 4 (4) 4 (4) 0.06–0.5 (0.18) 2–8 (5.8) 0.03–0.5 (0.18) 0.06–0.25 (0.13) 0.06–0.5 (0.24)
Lichtheimia corymbifera (6) 64 (64) 4 (4) 4 (4) 0.06–0.25 (0.12) 8 (8) 0.06–0.5 (0.22) 0.06–0.25 (0.20) 0.25–0.5 (0.31)
Lichtheimia ramosa (5) 64 (64) 4 (4) 4 (4) 0.125–0.5 (0.25) 2–8 (4.6) 0.03–0.5 (0.19) 0.06–0.25 (0.11) 0.06–0.25 (0.12)
Lichtheimia ornata (2) 64 4 4 0.25 2–8 0.06–0.125 0.06 0.25
Cunninghamella (8) 32–64 (58.7) 0.5–4 (2.59) 4 (4) 0.06–0.25 (0.09) 8 (8) 1–64 (19.0) 0.5–1 (0.71) 1–2 (1.54)
Cunninghamella bertholletiae (5) 32–64 (55.7) 1–4 (3.03) 4 (4) 0.06–0.25 (0.08) 8 (8) 16–64 (27.9) 0.5–1 (0.66) 1–2 (1.52)
Cunninghamella echinulata (3) 64 0.5–4 4 0.06–0.3 8 1–64 0.5–1 1–2
All isolates (66) 32–64 (63.3) 0.5–4 (3.8) 4 (4) 0.06–32 (0.62) 1–8 (5.5) 0.03–64 (0.66) 0.03–2 (0.33) 0.03–2 (0.48)
a MIC ranges (GMs) for 5-fluorocytosine (5-FC), micafungin (MCF), caspofungin (CAS), terbinafine (TBF), voriconazole (VCZ), itraconazole (ITZ), posaconazole (PCZ), and
amphotericin B (AMB). Genera are placed in line with the phylogenetic tree of Fig. 1 except for Rhizomucor. Within the genera, species are arranged according to their position in
the trees of Fig. 2.
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smallest range of variation over the entire set of Mucorales tested
(Table 2). Among the azoles, PCZ was the most effective antifun-
gal drug, with all strains being inhibited by concentrations of 2
g/ml. The genera Mucor (defined in a phylogenetic sense) and
Cunninghamella showed significantly lower degrees of suscepti-
bility to PCZ (Mann-Whitney, P  0.0001 for both genera). In
Rhizopus and Syncephalastrum, resistant strains occurred only
sporadically. The Lichtheimiaceae, represented by Lichtheimia and
Rhizomucor, completely lacked strains with reduced susceptibility
for PCZ.
Itraconazole was significantly less active against the Mucor-
aceae (defined in a phylogenetic sense) and Cunninghamella, in
which especially highMIC values were obtained (Mann-Whitney;
P 0.0001 for theMucoraceae as well as for Cunninghamella). In
contrast, the Lichtheimiaceae and Syncephalastrum (Syncephalas-
traceae), united in a well-supported clade in the LSU phylogram,
did not include strains with reduced susceptibility for ITZ.
For TBF, elevated MIC values were found only in the Mucor-
aceae, while the remaining families, namely, the Cunninghamel-
laceae, the Lichtheimiaceae, and the Syncephalastraceae, were fully
susceptible. The susceptibility ofCunninghamella to TBF is of spe-
cial importance because TBF was the only thoroughly active anti-
fungal against this genus in our study. The susceptibility to TBF in
the Mucoraceae appeared to be species dependent. Terbinafine
MICs were strikingly different between R. microsporus (geometric
mean [GM]MIC of 0.12g/ml) andR. arrhizus (GMMIC of 21.1
g/ml) (Mann-Whitney,P 0.0020) but not betweenM. circinel-
loides sensu lato (GM MIC of 5.66 g/ml) and the remaining
Mucor species (MICs of0.5 g/ml), although a trend was noted
(Mann-Whitney, P  0.0746). Susceptibility values of PCZ and
TBF were more heterogeneous in the Mucoraceae than in the re-
maining families.
Maximum susceptibilities were reached with PCZ (MIC 
0.03 g/ml) for Rhizopus arrhizus, ITZ (MIC  0.03 g/ml) for
Lichtheimia ramosa and Syncephalastrum “racemosum” species I,
and AMB (MIC 0.03g/ml) for Syncephalastrum “racemosum”
species II, while maximum resistance was observed with 5-FC
(MIC  64 g/ml) for nearly all strains tested and with ITZ
(MIC 64 g/ml) for 3 Cunninghamella strains.
Intrageneric differences of in vitro susceptibility inMucor and
Rhizopus ranged from 4 to 9 log2 dilution steps. With respect to
PCZ and ITZ, the genusMucor seems to contain a higher propor-
tion of strains that are resistant to or show reduced susceptibility
than Rhizopus (Mann-Whitney, P  0.0042 and P  0.0369, re-
spectively). In contrastMICs for VCZwere lower inMucor than in
Rhizopus (Mann-Whitney, P  0.0001). Some intraspecific vari-
ability of in vitro susceptibility was found in all genera tested (Ta-
ble 1). Strain CNRMA 04.1469 of R. microsporus deviated from
remaining strains of this species in its response to azoles.
DISCUSSION
A robust taxonomy and phylogeny of the Mucorales require spe-
cies validation by their ex-type materials. These reference materi-
als serve to calibrate additional strains examined, such that a tax-
onomic scaffold is provided, allowing meaningful comparison of
susceptibility data at the levels of species, genera, and families.
The genera Mucor and Rhizomucor have been misapplied in
somemedical publications. Judging from ITS sequence data, Rhi-
zomucor regularior (as R. variabilis var. regularior) was declared to
be a synonym of Mucor circinelloides (9) as suggested before (6,
36). The typical variety of Rhizomucor variabilis var. variabilis fits
elsewhere in the genusMucor (1, 10, 42), and recently Álvarez et al.
(9) proposed a name change toMucor irregularis.
Our study supports AMB as the antifungal of choice for most
genera ofMucorales. High MICs for AMB have been reported for
some genera not tested in the present study, such as Apophysomy-
ces and Saksenaea (7, 8, 12, 15, 35, 39). Results for Rhizopus and
Cunninghamella, however, are ambiguous, with MICs of 2 g/ml
for AMB. Similar results were obtained by other authors (1, 35, 39,
40). Alastruey-Izquierdo et al. (1) listed R. arrhizus and Cunning-
hamella bertholletiae with MIC ranges as wide as 0.03 to 32 g/ml
and 2 to 32 g/ml, respectively. In concordance with previous
studies (1, 5, 16), PCZ was the secondmost active drug, all strains
being inhibited by 2 g/ml or less (Table 2). The success rate of
therapy was reported to be 79% (20).
5-FC, MCF, and CAS were ineffective in all or nearly allMuco-
rales, showing highMIC/MEC values of32,4 (for 64 out of 66
strains), and 4 g/ml, respectively. This resistance is in accor-
dance with literature data (1, 5, 16, 40). With MICs consistently
1 g/ml in all Mucorales analyzed, VCZ was less active than
other azoles. The poor activity of this antifungal has been high-
lighted previously (e.g., references 1, 5, and 16).
Phylogenetic distances within theMucorales are reflected in in
vitro susceptibility profiles against antifungal drugs on all levels of
family, genus, species, and strain (Tables 1 and 2).Members of the
Lichtheimiaceae were consistently susceptible to PCZ, ITZ, TBF,
and AMB and exhibited smallerMIC ranges than theMucoraceae.
This matches with MIC values published (5, 16, 24, 32, 35, 39),
althoughTorres-Narbona et al. (40) andAlastruey-Izquierdo et al.
(1, 4) reported on individual Lichtheimia strains that were resis-
tant to PCZ, ITZ, and TBF and to ITZ, respectively.
The consistent in vitro activity of TBF against Cunninghamella
is of clinical relevance because the proportion of strains that are
resistant or have reduced susceptibility to PCZ and AMB is rela-
tively high in this genus, as shown in this study and by other
authors (1, 5, 39). Alastruey-Izquierdo et al. (1) tested the suscep-
tibility ofCunninghamella against TBF with a similar result. How-
ever, the authors found an individual strain resistant to TBF.
The species-specific differences in the susceptibility to TBF
found (Rhizopus arrhizus [resistant] versus R. microsporus [sus-
ceptible] andMucor circinelloides sensu lato [resistant] versus re-
mainingMucor species [susceptible]) were also in agreement with
earlier studies (1, 16). Significantly deviating resistance to azoles
was found in a single strain ofR.microsporus; Alastruey-Izquierdo
et al. (1) reported that TBF data were variable in that species.
In conclusion, AMB and PCZ were the most effective antifun-
gal agents against Mucorales. Susceptibility profiles (restricted to
the drugs that were at least partly active) differed significantly at
the familial, generic, and specific levels and reflected relationships
as referred from the phylogram; the Lichtheimiaceae were fully
susceptible to PCZ, ITZ, TBF, and AMB. Syncephalastrum (Syn-
cephalastraceae) members, positioned at the shortest distance to
theLichtheimiaceae in the LSUphylogram, showed similar suscep-
tibility profiles. The only difference was a single strain resistant to
PCZ. In contrast, theMucoraceaewere characterized by a reduced
susceptibility to PCZ, ITZ, and AMB and a lack of activity of TBF
in some species. While more Mucor strains were resistant to the
azoles, only Rhizopus strains exhibited a reduced susceptibility to
AMB. Susceptibility profiles of Cunninghamella (Cunninghamel-
laceae) resembled those of the Mucoraceae in terms of the high
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proportion of strains resistant to PCZ, ITZ, and AMB but differed
in terms of the lowMIC values for TBF. Judging fromMIC values
recorded by other authors, the Sakseneaeceae behave similarly to
Cunninghamella, their closest studied neighbor in the LSU phylo-
gram, in susceptibility tests. Along with Cunninghamella, they ex-
hibit a lack of or reduced susceptibility against PCZ, ITZ, and
AMB (5, 7, 8, 12, 35) and lowMIC values for TBF (7) (tested only
for Saksenaea).
Obviously, theMucorales cannot be considered as a single en-
tity from an antifungal perspective, since large differences in sus-
ceptibility exist between families, genera, species, and strains. The
reduced activity of AMB in Rhizopus andCunninghamella and the
high proportion of Mucor and Cunninghamella strains that were
less susceptible to PSZ are of practical importance because they
concern deviations for compounds that are otherwise recom-
mended for antifungal therapy of infections due to Mucorales.
Molecular identification of the etiologic agent is therefore re-
quired unless the susceptibility profile of the strain is known. In
genera with high intraspecific variation in their antifungal pro-
files, such asMucor andRhizopus, immediate susceptibility testing
is recommended to confirm the most effective and appropriate
compound.
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